RN1201 injection for newly diagnosed multiple myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with multiple myeloma and have a specific marker called BCMA on your cancer cells
- You are between 18 and 70 years old
- Your liver and kidney function are mostly normal (based on blood tests)
- Your heart is working well with an ejection fraction of at least 50% and no fluid around the heart
- You are well enough to care for yourself with minimal help (ECOG score 0–2)
- You can commit to all study visits and follow the treatment plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called RN1201, which uses a patient's own immune cells to fight multiple myeloma that has high-risk genetic features. The goal is to see if this therapy can help control the disease better after initial treatment.
This trial tests a new treatment called RN1201 for blood cancers like multiple myeloma, certain leukemias, and lymphomas that have not improved with standard treatments or have returned. The treatment targets specific markers on cancer cells (CD19 and BCMA) and may offer a new option for patients who have run out of standard choices.
This study tests an experimental drug called RN9101 for people with multiple myeloma that has returned or stopped responding to other treatments. The drug targets a protein called BCMA found on myeloma cells, and the goal is to see if it is safe and can help control the disease.
This trial tests an experimental therapy using immune cells (CAR-NK cells) designed to target and kill cancer cells in people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to treatment. The goal is to see if it is safe and effective.
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to other treatments and has spread to tissues outside the bone marrow.
This trial tests a new type of immune cell therapy (CAR-T) that targets a protein called CS1 on myeloma cells. It is for people whose myeloma has come back after a previous BCMA CAR-T treatment.
Hear when a new Multiple Myloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.